First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis.

Mario Scartozzi,Riccardo Giampieri,Bruno Daniele,Daris Ferrari,Sara Lonardi,Alberto Zaniboni,Luigi Cavanna,Gerardo Rosati,Nicoletta Pella,M. Giulia Zampino,Pietro Sozzi,Laura Casula,Lorena Cozzi,Domenico Germano,Marco Puzzoni,Cristian Loretelli,Vittorina Zagonel,Roberto Labianca,L. Frontini,Stefano Cascinu

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: Final results of the Italian Research Group for Digestive Tract Cancer (GISCAD) CENTRAL (ColorEctalvastiNTRiAlLdh) and SENTRAL (Serum angiogenesis-cENTRAL) analysis.

2016

e15116Background: Previous findings suggested that bevacizumab might improve clinical outcome in colorectal cancer patients with high basal LDH levels. We conducted a prospective trial to ascertain...

Keywords:

Bevacizumab
FOLFIRI
Cancer
Cancer research
Angiogenesis
Colorectal cancer
Pathology
Medicine
Basal (phylogenetics)
first line
Oncology
in patient
Internal medicine
digestive tract cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations